Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease

NCT02614131 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02614131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02614131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Terminated
Start date
December 31, 2015
Completion date
December 31, 2016
Enrollment
50 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, healthy, mild cognitive impairment